Establishment Labs Hldgs Inc Stock Price, News & Analysis

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focusing on women’s health in breast aesthetics and reconstruction, announced participation in two investment conferences. CEO Juan José Chacón-Quirós and CFO Renee Gaeta will present at the Jefferies Virtual London Healthcare Conference from November 17-19, 2020, and at the Stephens Virtual Investment Conference from November 16-20, 2020. Presentations will be webcast live on their investor relations website, with archived versions available post-event.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported Q3 2020 revenue of $22.8 million, consistent with the prior year's figure. The company's full-year revenue forecast is set at $80 million to $82 million, supported by a 23% reduction in operating expenses to $17.7 million. This quarter's gross profit reached $15.1 million, representing a margin of 66.6%. The cash balance stood at $81.4 million with a reduced net loss of $2.6 million. New product developments and regulatory advancements bolster future growth potential.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported preliminary third-quarter 2020 revenue between $22 million and $23 million, consistent with $22.9 million from 2019 and significantly up from $10.5 million in Q2 2020. The company's cash balance was approximately $81.0 million as of September 30, 2020. CEO Juan José Chacón-Quirós expressed satisfaction with the quarter's performance, highlighting strong growth and effective cost management. Full third-quarter results will be announced on November 9, 2020.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) has amended its distribution agreement with Puregraft LLC to extend their collaboration through the end of 2022. This agreement allows the company to continue offering advanced solutions for fat grafting as part of their MotivaHybrid® procedure, which utilizes the Motiva Implants® for natural breast augmentation. This partnership aligns with Establishment Labs' focus on women's health and expanding its innovative breast aesthetics product line.

Establishment Labs Holdings (NASDAQ: ESTA) announced the publication of a study in Plastic and Reconstructive Surgery-Global Open, revealing that hybrid breast reconstruction using Motiva Ergonomix implants enhances outcomes compared to traditional methods. Analyzing 56 reconstructions in 33 patients, the findings highlighted improved control of breast shape and reduced complication risks. CEO Juan José Chacón-Quirós emphasized the commitment to innovative technology for better patient outcomes. It's important to note that these implants are not yet approved for commercial distribution in the U.S.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) will participate in the 2020 Wells Fargo Virtual Healthcare Conference on September 9, 2020, at 2:00 PM ET. CEO Juan José Chacón-Quirós and CFO Renee Gaeta will represent the company. The event will be available via live webcast on the Establishment Labs investor relations website, with an archived version accessible post-event. Establishment Labs specializes in women's health, focusing on breast aesthetics and reconstruction, and offers products like Motiva Implants®, available in over 80 countries.

Establishment Labs Holdings Inc. (Nasdaq: ESTA) will announce its financial results for Q2 2020 on August 6, 2020, post-market. A conference call is scheduled for 5:30 PM ET to discuss these results. The company focuses on women's health, particularly in breast aesthetics and reconstruction, with a product range including the Motiva Implants® and the Divina® 3D Simulation System. Motiva Implants® have received FDA approval and are available in over 80 countries through various distribution channels.